Overseeing Innovative Therapy without Mistaking It for Research: A Function-Based Model Based on Old Truths, New Capacities, and Lessons from Stem Cells
Journal of Law, Medicine and Ethics 38 (2):286-302 (2010)
|Abstract||Should innovative therapy occur only within a research paradigm and under institutional review board oversight? The health risks from current human embryonic stem cell clinical applications have raised again a fundamental question addressed first in papers submitted to inform the writing of the Belmont Report. Revisiting the thinking underlying the Belmont Report, together with examining changed circumstances since then, leads to a new model for overseeing innovative therapy based on its unique risks and context, important changes since the Belmont Report, and new opportunities for addressing risks through safety and quality systems in health care|
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
|Through your library||Configure|
Similar books and articles
Ruth R. Faden, Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Xiao-Jiang Gao, Mark Greene, John A. Hansen, Patricia A. King, Stephen J. O.’Brien & David H. Sachs (2003). Public Stem Cell Banks: Considerations of Justice in Stem Cell Research and Therapy. Hastings Center Report 33 (6):13-27.
Jeremy Sugarman (2010). Reflections on Governance Models for the Clinical Translation of Stem Cells. Journal of Law, Medicine and Ethics 38 (2):251-256.
Howard J. Curzer (2004). The Ethics of Embryonic Stem Cell Research. Journal of Medicine and Philosophy 29 (5):533 – 562.
Michael R. Prieur, Joan Atkinson, Laurie Hardingham, David Hill, Gillian Kernaghan, Debra Miller, Sandy Morton, Mary Rowell, John F. Vallely & Suzanne Wilson (2006). Stem Cell Research in a Catholic Institution: Yes or No? Kennedy Institute of Ethics Journal 16 (1):73-98.
Maurie Markman (2004). The Research Misconception. International Journal of Applied Philosophy 18 (2):241-252.
Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Mark Greene, Patricia King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel & Davor Solter (2003). Safety Issues In Cell-Based Intervention Trials. Fertility and Sterility 80 (5):1077-1085.
Mark T. Brown (2009). Moral Complicity in Induced Pluripotent Stem Cell Research. Kennedy Institute of Ethics Journal 19 (1):pp. 1-22.
Ronald K. F. Fung & Ian H. Kerridge (2013). Uncertain Translation, Uncertain Benefit and Uncertain Risk: Ethical Challenges Facing First-in-Human Trials of Induced Pluripotent Stem (Ips) Cells. Bioethics 27 (2):89-96.
Insoo Hyun (2010). Allowing Innovative Stem Cell-Based Therapies Outside of Clinical Trials: Ethical and Policy Challenges. Journal of Law, Medicine and Ethics 38 (2):277-285.
Sorry, there are not enough data points to plot this chart.
Added to index2010-08-11
Total downloads1 ( #291,125 of 722,764 )
Recent downloads (6 months)0
How can I increase my downloads?